These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 20162620)

  • 1. Should antiviral treatment be extended to patients with chronic hepatitis B and mildly elevated alanine aminotransferase?
    Lok AS
    Hepatology; 2010 Apr; 51(4):1107-9. PubMed ID: 20162620
    [No Abstract]   [Full Text] [Related]  

  • 2. A call for attention and trials on hepatitis B e antigen-negative, alanine aminotransferase-normal chronic hepatitis B virus infection.
    Zhao H; Miao R
    Hepatology; 2009 Aug; 50(2):658; author reply 658-9. PubMed ID: 19585650
    [No Abstract]   [Full Text] [Related]  

  • 3. Hepatitis B e antigen-negative patients with persistently normal alanine aminotransferase levels and hepatitis B virus DNA > 2000 IU/mL.
    Dai CY; Chuang WL; Huang JF; Yu ML
    Hepatology; 2009 Feb; 49(2):704-5; author reply 705-6. PubMed ID: 19177587
    [No Abstract]   [Full Text] [Related]  

  • 4. [Predictors for virologic response in management of chronic hepatitis B].
    Lee JM; Ahn SH
    Korean J Hepatol; 2010 Mar; 16(1):1-4. PubMed ID: 20375637
    [No Abstract]   [Full Text] [Related]  

  • 5. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy.
    Leung NW; Lai CL; Chang TT; Guan R; Lee CM; Ng KY; Lim SG; Wu PC; Dent JC; Edmundson S; Condreay LD; Chien RN;
    Hepatology; 2001 Jun; 33(6):1527-32. PubMed ID: 11391543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Lamivudine treatment for hepatitis B].
    Lamivudine Clincal Practice Group
    Zhonghua Gan Zang Bing Za Zhi; 2004 Jul; 12(7):425-8. PubMed ID: 15487066
    [No Abstract]   [Full Text] [Related]  

  • 7. Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B.
    Gish RG; Chang TT; Lai CL; de Man R; Gadano A; Poordad F; Yang J; Brett-Smith H; Tamez R
    J Viral Hepat; 2010 Jan; 17(1):16-22. PubMed ID: 19622117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum alanine aminotransferase flares during interferon treatment of chronic hepatitis B: is sustained clearance of HBV DNA dependent on levels of pretreatment viremia?
    Nair S; Perrillo RP
    Hepatology; 2001 Nov; 34(5):1021-6. PubMed ID: 11679974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A 7-year study of lamivudine therapy for hepatitis B virus e antigen-positive chronic hepatitis B patients in China.
    Yao GB; Zhu M; Cui ZY; Wang BE; Yao JL; Zeng MD
    J Dig Dis; 2009 May; 10(2):131-7. PubMed ID: 19426396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changing landscape of antiviral resistance management in chronic hepatitis B.
    Nguyen T; Locarnini S; Desmond P
    J Gastroenterol Hepatol; 2008 Sep; 23(9):1314-7. PubMed ID: 18853991
    [No Abstract]   [Full Text] [Related]  

  • 11. [Chronic hepatitis B virus (HBV) infection: usefulness of the combination of HBeAg and ALT determination to predict a high HBV-DNA level and therefore the necessity of referral to a specialist for possible antiviral treatment].
    Veldhuijzen IK; Mostert MC; Niesters HG; Richardus JH; de Man RA
    Ned Tijdschr Geneeskd; 2008 Jun; 152(25):1426-30. PubMed ID: 18624006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of chronic hepatitis B with lamivudine.
    Khokhar N; Gill ML; Alam AY
    J Coll Physicians Surg Pak; 2005 Feb; 15(2):78-80. PubMed ID: 15730830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Lamivudine treatment consensus from relative experts in 2003].
    Lamivudine Clinical Practice Group
    Zhonghua Gan Zang Bing Za Zhi; 2003 Aug; 11(8):497-9. PubMed ID: 12939188
    [No Abstract]   [Full Text] [Related]  

  • 14. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian Hepatitis Lamivudine Trial Group.
    Chien RN; Liaw YF; Atkins M
    Hepatology; 1999 Sep; 30(3):770-4. PubMed ID: 10462384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The predictive value of liver fibrosis in determining the effectiveness of interferon and lamivudine therapies for chronic hepatitis B.
    Shindo M; Hamada K; Nishioji K; Muramatsu A; Oda Y; Okuno T
    J Gastroenterol; 2004; 39(3):260-7. PubMed ID: 15065004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiviral therapy for chronic hepatitis B: are we doing any good to patients?
    Wong VW; Sung JJ
    J Antimicrob Chemother; 2009 Aug; 64(2):223-6. PubMed ID: 19468026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical trial results and treatment resistance with lamivudine in hepatitis B.
    Wright TL
    Semin Liver Dis; 2004; 24 Suppl 1():31-6. PubMed ID: 15192799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multicenter study of lamivudine treatment in 33 patients with hepatitis B after liver transplantation.
    Fontana RJ; Hann HW; Wright T; Everson G; Baker A; Schiff ER; Riely C; Anschuetz G; Riker-Hopkins M; Brown N;
    Liver Transpl; 2001 Jun; 7(6):504-10. PubMed ID: 11443577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B.
    van Zonneveld M; Honkoop P; Hansen BE; Niesters HG; Darwish Murad S; de Man RA; Schalm SW; Janssen HL
    Hepatology; 2004 Mar; 39(3):804-10. PubMed ID: 14999700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Role of ribavirin in the treatment of chronic hepatitis B].
    Galban García E; Vega Sánchez H; Gra Oramas B; Rodríguez Pérez A; Doval Hernández MA; Haedo Castro D; Rolo F; Lorenzo Morejón I; Ramos Sánchez V
    Gastroenterol Hepatol; 2000 Apr; 23(4):165-9. PubMed ID: 10863856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.